Aardvark Therapeutics voluntarily paused dosing and enrollment in its Phase 3 HERO trial of ARD‑101 for hyperphagia in Prader‑Willi syndrome after routine safety monitoring in a healthy volunteer study revealed reversible cardiac observations at above‑target doses. The company said it will conduct a comprehensive data review to determine next steps and delayed its expected topline readout. Market reaction was swift: Aardvark shares fell more than 50% as investors priced in uncertainty for the program and timing.